Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Treatment with Bitter Melon Juice Blocks Growth of Pancreatic Cancer Cells

By BiotechDaily International staff writers
Posted on 25 Mar 2013
Image: Momordica charantia (Photo courtesy of Sayat Arslanlioglu).
Image: Momordica charantia (Photo courtesy of Sayat Arslanlioglu).
Juice of the bitter melon (Momordica charantia), which has been used in natural Asian medicine for treatment of diabetes, was found to kill pancreatic cancer cells both in vitro and in vivo without noticeable toxicity to normal tissues.

Investigators at the University of Colorado (Aurora, USA) worked with cultures of the pancreatic cancer cell lines BxPC-3, MiaPaCa-2, AsPC-1, and Capan-2 and with a xenograft model of MiaPaCa-2 tumors growing in nude mice. The cell cultures were treated with bitter melon juice while the mice were fed lyophilized bitter melon juice for a period of six weeks.

Results published in the March 8, 2013, online edition of the journal Carcinogenesis revealed that bitter melon juiced decreased cell viability in all four pancreatic carcinoma cell lines by inducing strong apoptotic death. Oral administration of lyophilized bitter melon juice for six weeks inhibited MiaPaCa-2 tumor xenograft growth by 60% without noticeable toxicity in nude mice.

At the molecular level, bitter melon juice was shown to activate caspases and alter expression of Bcl2 family members and cytochrome-c release into the cytosol. Additionally, it decreased survivin and XIAP (X-linked inhibitor of apoptosis protein) but increased p21, CHOP (DNA-damage-inducible transcript 3), and phosphorylated MAPKs (ERK1/2 and p38) levels. In addition, bitter melon juice activated AMP-activated protein kinase (AMPK), a biomarker for cellular energy status. An AMPK inhibitor (Compound C) reversed bitter melon juice-induced caspase 3 activation, suggesting activated-AMPK involvement in the induced apoptosis.

Immunohistochemical analyses of MiaPaCa-2 xenografts showed that bitter melon juice inhibited proliferation, induced apoptosis, and activated AMPK in vivo.

“Three years ago researchers showed the effect of bitter melon extract on breast cancer cells only in a Petri dish. This study goes much, much farther. We used the juice—people especially in Asian countries are already consuming it in quantity. We show that it affects the glucose metabolism pathway to restrict energy and kill pancreatic cancer cells,” said senior author Dr. Rajesh Agarwal, professor of pharmaceutical sciences at the University of Colorado. “It is a very exciting finding. Many researchers are engineering new drugs to target cancer cells’ ability to supply themselves with energy, and here we have a naturally-occurring compound that may do just that.”

Related Links:
University of Colorado


Channels

Genomics/Proteomics

view channel
Image: The photomicrograph shows the head of a mouse embryo in which the pericytes are visible as blue dots along the blood vessel (Photo courtesy of the University of Gothenburg).

Genetically Engineered Mouse Model Reveals Key to Formation of the Blood-Brain Barrier

Use of a mouse model that had been genetically engineered to lack the gene that encodes the forkhead transcription factor Foxf2 has helped to explain how pericytes, cells that line the capillaries, form... Read more

Therapeutics

view channel
Image: A photmicrograph of medium spiny neurons (yellow) with nuclear inclusions (orange), which occur as part of the Huntington\'s disease process. Several neurons are colored yellow and have a large central core with up to two dozen tendrils branching out of them. The core of the neuron in the foreground contains an orange blob about a quarter of its diameter (Photo courtesy of Wikimedia Commons).

Seeding Assay May Boost Search for Huntington's Disease Drugs

An assay technique that measures seeding of mutant huntingtin aggregates in cerebral spinal fluid (CSF) may identify individuals with Huntington's disease (HD) that have not yet become symptomatic and... Read more

Business

view channel

Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers. The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.